secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0000950170-24-032826
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya reports Q4 net loss $29.9M; cash $104.6M; TN-201 data and TN-401 dosing expected H2 2024
--------------------------------------------------------------------------------

- Net loss $29.9M ($0.40/sh) Q4 2023; full year net loss $124.1M ($1.68/sh).
- Cash, equivalents and investments $104.6M at Dec 31, 2023; Feb 2024 financing adds $46.5M net, extending runway into H2 2025.
- Initial safety and biomarker data from MyPeak-1 Phase 1b of TN-201 for MYBPC3 HCM expected H2 2024; first patient dosed Oct 2023.
- RIDGE-1 Phase 1b of TN-401 for PKP2 ARVC on track to dose first patient H2 2024; FDA Fast Track granted Nov 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000095017024032826/0000950170-24-032826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000095017024032826/tnya-20240318.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-032826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer